Parse and Graph Launch Massive AI-Driven Immune Atlas
Seattle and Vienna, January 20, 2026 — Parse Biosciences and Graph Therapeutics have announced a strategic partnership to create...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Seattle and Vienna, January 20, 2026 — Parse Biosciences and Graph Therapeutics have announced a strategic partnership to create...
